2C-G

2C-G
Names
Preferred IUPAC name
2-(2,5-Dimethoxy-3,4-dimethylphenyl)ethan-1-amine
Identifiers
CAS Number
  • 207740-18-9 checkY
3D model (JSmol)
  • Interactive image
ChEMBL
  • ChEMBL127202 checkY
ChemSpider
  • 21106224 checkY
PubChem CID
  • 22238091
UNII
  • DTG7FMO01J checkY
CompTox Dashboard (EPA)
  • DTXSID70174848 Edit this at Wikidata
InChI
  • InChI=1S/C12H19NO2/c1-8-9(2)12(15-4)10(5-6-13)7-11(8)14-3/h7H,5-6,13H2,1-4H3 checkY
    Key: NFOHGLKGLZIHJQ-UHFFFAOYSA-N checkY
  • InChI=1/C12H19NO2/c1-8-9(2)12(15-4)10(5-6-13)7-11(8)14-3/h7H,5-6,13H2,1-4H3
    Key: NFOHGLKGLZIHJQ-UHFFFAOYAX
  • COc1c(C)c(C)c(cc1CCN)OC
Properties
Chemical formula
C12H19NO2
Molar mass 209.289 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references
Chemical compound

2C-G is a psychedelic phenethylamine of the 2C-series. First synthesized by Alexander Shulgin,[1] it is sometimes used as an entheogen. It has structural and pharmacodynamic properties similar to 2C-D and Ganesha. Like many of the phenethylamines in PiHKAL, 2C-G and its homologs have only been taken by Shulgin and a small test group, making it difficult to ensure completeness when describing effects.

Chemistry

2C-G is 3,4-dimethyl-2,5-dimethoxyphenethylamine, with the formula C
12
H
19
NO
2
.

Dosage and effects

In Shulgin's book PiHKAL, the dosage range is listed as 20 to 35 mg.[1] Effects are similar to the related Ganesha, and are extremely long lasting; the duration is 18–30 hours. Visual effects are muted or absent, and it is described in PiHKAL as an "insight-enhancer".[1] Unlike other members of the 2C-series, 2C-G is nearly as potent as its amphetamine form.

Homologs

Several homologs of 2C-G were also synthesized by Shulgin. These include 2C-G-3, 2C-G-5, and 2C-G-N. Some, such as 2C-G-1, 2C-G-2, 2C-G-4, and 2C-G-6 are possible to synthesize in principle but impossible or extraordinarily difficult to do so in practice.

2C-G-1 CAS: 2888537-47-9

The synthesis of this compound has not been reported, but it is described prophetically in WO2022271982

2C-G-1
2C-G-2 CAS: 2888537-48-0

The synthesis of this compound has not been reported, but it is described prophetically in WO2022271982

2C-G-2
2C-G-3 CAS: 207740-19-0

Dosage: 16–25 mg
Duration: 12–24 hours
Effects: Some visual effects. General euphoria with an underlying sense of paranoia.

2C-G-3
2C-G-4 CAS: 952006-59-6

Synthesized but not tested.

2C-G-4
2C-G-5 CAS: 207740-20-3

Dosage: 10–16 mg
Duration: 32–48 hours
Effects: Similar to 2C-B for some users. General euphoria (sometimes followed by irritability), often leading to tiredness (likely due to duration).

2C-G-5
2C-G-6 CAS: 2888537-49-1

The synthesis of this compound has not been reported, but it is described prophetically in WO2022271982

2C-G-6
2C-G-N CAS: 207740-21-4

Dosage: 20–40 mg
Duration: 20–30 hours
Effects: Stimulation similar to that caused by amphetamines. General sense of unease or unfriendliness for most. 2C-G-N is sometimes called 2C-NPH due to the Naphthalene portion of the molecule.

2C-G-N

Legal status

Canada

As of October 31, 2016; 2C-G is a controlled substance (Schedule III) in Canada.[2]

United Kingdom

2C-G and all other compounds featuring in PiHKAL are Class A drugs in the United Kingdom.

United States

In the United States 2C-G is considered a Schedule 1 controlled substance as a positional isomer of 2C-E and 2,5-Dimethoxy-4-methylamphetamine (DOM).[3]

See also

References

  1. ^ a b c PiHKAL entry on 2C-G
  2. ^ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.
  3. ^ "Lists of: Scheduling Actions - Controlled Substances - Regulated Chemicals" (PDF). Drug Enforcement Administration. February 2023.

External links

  • [1], [2], [3], [4] PiHKAL entries on the homologues
  • 2C-G Entry in PiHKAL • info
  • 2C-G-3 Entry in PiHKAL • info
  • 2C-G-4 Entry in PiHKAL • info
  • 2C-G-5 Entry in PiHKAL • info
  • 2C-G-N Entry in PiHKAL • info
  • v
  • t
  • e
2C family of psychedelics
  • v
  • t
  • e
Psychedelics
(5-HT2A
agonists)
Benzofurans
Lyserg‐
amides
Phenethyl‐
amines
2C-x
25x-NBx
25x-NB
25x-NB3OMe
  • 25B-NB3OMe
  • 25C-NB3OMe
  • 25D-NB3OMe
  • 25E-NB3OMe
  • 25H-NB3OMe
  • 25I-NB3OMe
  • 25N-NB3OMe
  • 25P-NB3OMe
  • 25T2-NB3OMe
  • 25T4-NB3OMe
  • 25T7-NB3OMe
  • 25TFM-NB3OMe
25x-NB4OMe
  • 25B-NB4OMe
  • 25C-NB4OMe
  • 25D-NB4OMe
  • 25E-NB4OMe
  • 25H-NB4OMe
  • 25I-NB4OMe
  • 25N-NB4OMe
  • 25P-NB4OMe
  • 25T2-NB4OMe
  • 25T4-NB4OMe
  • 25T7-NB4OMe
  • 25TFM-NB4OMe
25x-NBF
25x-NBMD
  • 25B-NBMD
  • 25C-NBMD
  • 25D-NBMD
  • 25E-NBMD
  • 25F-NBMD
  • 25H-NBMD
  • 25I-NBMD
  • 25P-NBMD
  • 25T2-NBMD
  • 25T7-NBMD
  • 25TFM-NBMD
25x-NBOH
25x-NBOMe
Atypical structures
25x-NMx
  • 25B-NMe7BF
  • 25B-NMe7BT
  • 25B-NMe7Bim
  • 25B-NMe7Box
  • 25B-NMe7DHBF
  • 25B-NMe7Ind
  • 25B-NMe7Indz
  • 25B-NMePyr
  • 25I-NMe7DHBF
  • 25I-NMeFur
  • 25I-NMeTHF
  • 25I-NMeTh
N-(2C)-fentanyl
  • N-(2C-B) fentanyl
  • N-(2C-C) fentanyl
  • N-(2C-D) fentanyl
  • N-(2C-E) fentanyl
  • N-(2C-G) fentanyl
  • N-(2C-H) fentanyl
  • N-(2C-I) fentanyl
  • N-(2C-IP) fentanyl
  • N-(2C-N) fentanyl
  • N-(2C-P) fentanyl
  • N-(2C-T) fentanyl
  • N-(2C-T-2) fentanyl
  • N-(2C-T-4) fentanyl
  • N-(2C-T-7) fentanyl
  • N-(2C-TFM) fentanyl
3C-x
4C-x
DOx
HOT-x
MDxx
Mescaline (subst.)
TMAs
  • TMA
  • TMA-2
  • TMA-3
  • TMA-4
  • TMA-5
  • TMA-6
Others
Piperazines
Tryptamines
alpha-alkyltryptamines
x-DALT
x-DET
x-DiPT
x-DMT
x-DPT
Ibogaine-related
x-MET
x-MiPT
Others
Others
Dissociatives
(NMDAR
antagonists)
Arylcyclo‐
hexylamines
Ketamine-related
PCP-related
Others
Adamantanes
Diarylethylamines
Morphinans
Others
Deliriants
(mAChR
antagonists)
Others
Cannabinoids
(CB1 agonists)
Natural
Synthetic
AM-x
CP x
HU-x
JWH-x
Misc. designer cannabinoids
D2 agonists
GABAA
enhancers
Inhalants
(Mixed MOA)
κOR agonists
Oneirogens
Others